The anticipated size of the direct-to-consumer genetic testing market in 2022 was US$ 1,485.1 million and is estimated to be US$ 1,645.5 million in 2023. direct-to-consumer (DTC) genetic testing has become a rising popularity in recent years, because of the advancements in technology that have made genealogy testing more available and economical. Future Market Insights has mentioned in its reports that the direct-to-consumer genetic testing market will expand at a CAGR of 11.40% between 2023 and 2033, totaling around US$ 4,843.4 million by 2033.
Direct-to-consumer genetic testing is an emerging service where various aspects of an individual such as disease complications, health, and similar other traits are provided. Customers are directly marketed to genetic tests via broadcast, newspaper ads, or online databases.
Customers need to submit a DNA sample to the company and obtain results via a secure platform or in a written format. Direct-to-consumer genetic testing enables users to get access to their hereditary or genetic information without seeking help from a medical care provider or health insurance company. It is also known as home DNA testing, which delivers insights into the ancestry and other biological aspects of an individual.
Attributes | Details |
---|---|
Projected Forecast Value (2022) | US$ 1,485.1 million |
Projected Forecast Value (2023) | US$ 1,645.5 million |
Projected Forecast Value (2033) | US$ 4,843.4 million |
Growth rate | 11.4% CAGR |
Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global direct-to-consumer genetic testing (DTC-GT) market grew at a CAGR of 9.8% between 2017 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 11.4% between 2023 and 2033.
Demand for direct-to-consumer genetic testing will continue to grow at a rapid pace in the forthcoming years owing to their positive impact on human health in terms of safety, easy availability, and adaptability. Growing public awareness about safety and self-curiosity to know oneself better is also likely to drive the market.
Increasing awareness regarding the importance of genetic variations in a broad array of phenotypes that involves different ailments is set to aid growth. Results of these tests showcase whether an individual has a genetic tendency to a specific disease or phenotype of concern, which can be diagnosed at the earliest to initiate efficient disease management.
First sequencing of the human genome, advancements in genome sequencing technology have enabled rapid growth in the field of genomics research. It has further led direct-to-consumer genetic testing to evolve into a new service. The global direct-to-consumer genetic testing market has influenced many people since these tests provide valid information regarding several health risks, personal traits, and overall wellness. The rapid shift of people from clinical laboratories to DTC-GT is another crucial factor that is anticipated to drive the market in the forecast period.
Usage of Genetic Marketers for Affirming the Existence of Kinship Relationships
The use of genetic markers to affirm the existence of kinship relationships between individuals is a relatively simple task that is routinely carried out in forensic laboratories or by using publicly available tests. Introduction of microarray genetic analysis platforms with hundreds of thousands of SNPs will promote the implementation of advanced algorithms to openly test for more secluded genealogical relationships among individuals.
Such personal data is already used in genetic tests, as well as with recently designed statistical methods from evolutionary biology. It is capable of providing a thorough assessment of ancestry and admixture. During the evaluation period, these factors are expected to provide lucrative opportunities for key players in the global direct-to-consumer genetic testing market.
Harmful Genetic Disorders and Chemicals Affecting DNA Arises
Direct-to-consumer genetic testing plays an important role in the healthcare sector. Even though it has superior qualities, it does come along with a few drawbacks. Direct-to-consumer genetic testing may provide a constrained snapshot of a patient's health. Genetic factors that could lead to disorders like cystic fibrosis or Huntington's disease, as well as environmental factors such as harmful chemicals affecting DNA or exposure to ultraviolet rays are not considered for genetic testing.
When people make critical decisions about disease treatment and prevention depending on their test results, the issue occurs when certain ailments are ignored until they start to alter their health. Unforeseen facts about one's wellness, family dynamics, or ancestry can also be distressing or disconcerting. Enough scientific evidence is not provided to corroborate a specific genetic variant to a particular disease or functionality. Testing companies use their customers' genetic information illegally or if the data is stolen, genetic privacy may be compromised.
Presence of Various Home DNA Testing Kit Manufacturers to Boost Growth
North America holds a major portion of the market with a value share of 48.2% whereas the United States holds a direct-to-consumer genetic testing market share of about 42.9% as it is expected to continue to dominate the market in North America throughout the forecast period.
United States of America is one of the dominant and most competitive markets for direct-to-consumer genetic testing in the world. Presence of a large number of manufacturers is expected to result in the production of relatively low-cost units, which would spur the market.
Implementation of stringent norms by regulatory bodies such as the FDA to follow best practices and report information about adverse events associated with these test kits is set to aid growth in the country.
International Companies to Help Provide Genetic Information to Customers
Within Asia Pacific, Japan is said to hold an important part of the market with a value share of 6.3% whereas China market is said to grow at a CAGR of 12.7% in East Asia.
Although only a tiny proportion of the population in India uses genetic screening services growing at a CAGR of 15.3%, demand from customers is rising exponentially. On account of this, many international companies are expected to enter the Asia Pacific’s direct-to-consumer genetic testing market and aim to provide cost-effective services where Australia grows at a CAGR of 8.9%
Ongoing Development of Genome Sequencing Technology to Push Sales
Germany is set to exhibit a CAGR of nearly 7.1% in Europe where it holds 32.7% of the market share in the direct-to-consumer genetic testing market during the forecast period whereas the United Kingdom grows at a CAGR of 11.8%. Increasing awareness of health-influencing genetic factors is expected to grow steadily, thereby pushing the German market.
Breakthroughs in genetic technology, largely defined by cost-effective and more efficient genetic analysis are set to increase at a fast pace. Rising genomic awareness owing to the outcome of genome-wide association studies (GWAS) is expected to aid growth.
GWAS enables a better understanding of genotype-phenotype comparisons and provides additional data on the risks of having genetic diseases. Spurred by the aforementioned factors, the market is likely to grow in Germany.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Ancestry Tests to Exhibit High Growth with Urgent Need to Know Genetic Information
The ancestry tests segment exhibited high growth at a CAGR of 10.9%, with a projected share of about 38.2% in the global market in the same year. Ancestry tests provide better results about an individual’s hereditary information.
Increasing interest of people in knowing about their family tree and ancestors is projected to drive sales of ancestry tests in the future. High demand for cheek swabs or saliva-based DNA test kits in developed regions such as Europe and North America would foster the segment.
Medical Care Providers Are Adopting Single Nucleotide Polymorphism Chips
The single nucleotide polymorphism chips segment held a market share of around 64.5% and is expected to showcase gradual growth over the forecast period. The ability of single nucleotide polymorphism chips to work well on degraded DNA is anticipated to drive the segment.
Single nucleotide polymorphism chips have lower mutation rates, as compared to short tandem repeats (STRs) as it is thus capable of enabling kinship testing and this property would foster the segment in the upcoming decade.
Saliva Samples Be Highly Preferred for Genetic Testing
The saliva segment held a direct-to-consumer genetic testing market share of 67.0%. Saliva samples are cost-effective, pain-free, and user-friendly.
Blood sampling is considered to be a gold standard for sample collection, the participation rate is less compared to saliva samples as this factor is projected to create new opportunities for growth during the forecast period.
Retail Sales to Surge in the Genetic Testing Market
Retail sales segment held the highest direct-to-consumer genetic testing market share of nearly 79.5%. Easy availability of DTC-GT without the involvement of any healthcare professional is propelling sales through retail channels.
Some of the prominent players in the global market are-
Some of the recent industry developments in the global direct-to-consumer genetic testing market are:
Report Attribute | Details |
---|---|
Growth Rate | CAGR of 11.40% from 2023 to 2033 |
Market value in 2023 | US$ 1,645.5 million |
Market value in 2033 | US$ 4,843.4 million |
Base Year for Estimation | 2022 |
Historical Data | 2017 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | US$ million for Value and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization & Pricing | Available on Request |
The industry in 2023 is valued at US$ 1,645.5 million.
The market CAGR through 2033 is 11.40%.
From 2017 to 2022, the market registered a CAGR of 9.8%.
By 2033, the market will reach US$ 4,843.4 million.
Harmful genetic disorders and chemicals affecting DNA Arises are restraining market growth.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2017-2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2022 and Forecast 2023 to 2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2017-2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033
5.3.1. Pharmacogenetics Tests
5.3.2. Carrier Screening Tests
5.3.3. Genetic Health Risk (GHR) Tests
5.3.4. Cancer Predisposition Tests
5.3.5. Low-Risk General Wellness Tests
5.3.6. Ancestry Tests
5.4. Y-o-Y Growth Trend Analysis By Product, 2017-2022
5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
6. Global Market Analysis 2017-2022 and Forecast 2023 to 2033, By Technology
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2017-2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2023 to 2033
6.3.1. Single Nucleotide Polymorphism Chip
6.3.2. Whole Genome Sequencing
6.4. Y-o-Y Growth Trend Analysis By Technology, 2017-2022
6.5. Absolute $ Opportunity Analysis By Technology, 2023 to 2033
7. Global Market Analysis 2017-2022 and Forecast 2023 to 2033, By Sample
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Sample , 2017-2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sample , 2023 to 2033
7.3.1. Saliva
7.3.2. Urine
7.3.3. Blood
7.4. Y-o-Y Growth Trend Analysis By Sample , 2017-2022
7.5. Absolute $ Opportunity Analysis By Sample , 2023 to 2033
8. Global Market Analysis 2017-2022 and Forecast 2023 to 2033, By Sales Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Sales Channel, 2017-2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sales Channel, 2023 to 2033
8.3.1. Institutional Sales
8.3.1.1. Hospitals
8.3.1.2. Specialty Clinics
8.3.1.3. Diagnostic Laboratories
8.3.1.4. Others
8.3.2. Retail Sales
8.3.2.1. Retail Pharmacies
8.3.2.2. Online Sales
8.4. Y-o-Y Growth Trend Analysis By Sales Channel, 2017-2022
8.5. Absolute $ Opportunity Analysis By Sales Channel, 2023 to 2033
9. Global Market Analysis 2017-2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017-2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2017-2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017-2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. U.S.
10.2.1.2. Canada
10.2.2. By Product
10.2.3. By Technology
10.2.4. By Sample
10.2.5. By Sales Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.3.3. By Technology
10.3.4. By Sample
10.3.5. By Sales Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2017-2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017-2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Product
11.2.3. By Technology
11.2.4. By Sample
11.2.5. By Sales Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By Technology
11.3.4. By Sample
11.3.5. By Sales Channel
11.4. Key Takeaways
12. Western Europe Market Analysis 2017-2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017-2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. U.K.
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Product
12.2.3. By Technology
12.2.4. By Sample
12.2.5. By Sales Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By Technology
12.3.4. By Sample
12.3.5. By Sales Channel
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2017-2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017-2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Product
13.2.3. By Technology
13.2.4. By Sample
13.2.5. By Sales Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By Technology
13.3.4. By Sample
13.3.5. By Sales Channel
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2017-2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017-2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Product
14.2.3. By Technology
14.2.4. By Sample
14.2.5. By Sales Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By Technology
14.3.4. By Sample
14.3.5. By Sales Channel
14.4. Key Takeaways
15. East Asia Market Analysis 2017-2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017-2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Product
15.2.3. By Technology
15.2.4. By Sample
15.2.5. By Sales Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product
15.3.3. By Technology
15.3.4. By Sample
15.3.5. By Sales Channel
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2017-2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017-2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Product
16.2.3. By Technology
16.2.4. By Sample
16.2.5. By Sales Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Product
16.3.3. By Technology
16.3.4. By Sample
16.3.5. By Sales Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. U.S.
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Product
17.1.2.2. By Technology
17.1.2.3. By Sample
17.1.2.4. By Sales Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Product
17.2.2.2. By Technology
17.2.2.3. By Sample
17.2.2.4. By Sales Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Product
17.3.2.2. By Technology
17.3.2.3. By Sample
17.3.2.4. By Sales Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Product
17.4.2.2. By Technology
17.4.2.3. By Sample
17.4.2.4. By Sales Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Product
17.5.2.2. By Technology
17.5.2.3. By Sample
17.5.2.4. By Sales Channel
17.6. U.K.
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Product
17.6.2.2. By Technology
17.6.2.3. By Sample
17.6.2.4. By Sales Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Product
17.7.2.2. By Technology
17.7.2.3. By Sample
17.7.2.4. By Sales Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Product
17.8.2.2. By Technology
17.8.2.3. By Sample
17.8.2.4. By Sales Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Product
17.9.2.2. By Technology
17.9.2.3. By Sample
17.9.2.4. By Sales Channel
17.10. Poland
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Product
17.10.2.2. By Technology
17.10.2.3. By Sample
17.10.2.4. By Sales Channel
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Product
17.11.2.2. By Technology
17.11.2.3. By Sample
17.11.2.4. By Sales Channel
17.12. Czech Republic
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Product
17.12.2.2. By Technology
17.12.2.3. By Sample
17.12.2.4. By Sales Channel
17.13. Romania
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Product
17.13.2.2. By Technology
17.13.2.3. By Sample
17.13.2.4. By Sales Channel
17.14. India
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Product
17.14.2.2. By Technology
17.14.2.3. By Sample
17.14.2.4. By Sales Channel
17.15. Bangladesh
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Product
17.15.2.2. By Technology
17.15.2.3. By Sample
17.15.2.4. By Sales Channel
17.16. Australia
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Product
17.16.2.2. By Technology
17.16.2.3. By Sample
17.16.2.4. By Sales Channel
17.17. New Zealand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Product
17.17.2.2. By Technology
17.17.2.3. By Sample
17.17.2.4. By Sales Channel
17.18. China
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Product
17.18.2.2. By Technology
17.18.2.3. By Sample
17.18.2.4. By Sales Channel
17.19. Japan
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Product
17.19.2.2. By Technology
17.19.2.3. By Sample
17.19.2.4. By Sales Channel
17.20. South Korea
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Product
17.20.2.2. By Technology
17.20.2.3. By Sample
17.20.2.4. By Sales Channel
17.21. GCC Countries
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Product
17.21.2.2. By Technology
17.21.2.3. By Sample
17.21.2.4. By Sales Channel
17.22. South Africa
17.22.1. Pricing Analysis
17.22.2. Market Share Analysis, 2022
17.22.2.1. By Product
17.22.2.2. By Technology
17.22.2.3. By Sample
17.22.2.4. By Sales Channel
17.23. Israel
17.23.1. Pricing Analysis
17.23.2. Market Share Analysis, 2022
17.23.2.1. By Product
17.23.2.2. By Technology
17.23.2.3. By Sample
17.23.2.4. By Sales Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Product
18.3.3. By Technology
18.3.4. By Sample
18.3.5. By Sales Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. 23andMe
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Ancestry DNA
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Color Genomics, Inc.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Genetic Technology (EasyDNA)
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Full Genomes Corporation, Inc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Helix OpCo LLC
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. IDENTIGENE, LLC/ DNA Diagnostics Center
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Living DNA Ltd
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. MyHeritage Ltd
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Prenetics Limited
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Family Tree DNA
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Interleukin Genetics/orig3n
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Counsyl/Myriad Genetics, Inc.
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.14. Veritas Genetics
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.15. Fulgent Genomics
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports